全外显子基因检测是一种针对家族性疾病、遗传代谢性疾病以及罕见疾病的检测技术。它是对蛋白编码的序列直接测序，从而发现蛋白结构的变异，还能发现变异频率低于1%的罕见变异。该检测主要用于寻找遗传疾病相关的基因变异情况，进行遗传病的诊断、鉴别诊断、排除诊断， ...

The US company said that results from the Alpha-CORRECT trial saw its colon cancer diagnostic Oncodetect achieving a ...

New Evidence Validates Oncodetect's™ Ability to Detect Molecular Residual Disease and Predict Recurrence in Colorectal Cancer Patients ...

Optimized methods and protocols for single cell and single nucleus RNA sequencing of preserved skeletal muscle provide an important resource for obtaining high-quality single cell genomic material ...

全外显子基因检测是一种针对家族性疾病、遗传代谢性疾病以及罕见疾病的检测技术。它是对蛋白编码的序列直接测序，从而发现蛋白结构的变异，还能发现变异频率低于1%的罕见变异。该检测主要用于寻找遗传疾病相关的基因变异情况，进行遗传病的诊断、鉴别诊断、排除诊断， ...

The short answer is yes, PCOS has a complex genetic predisposition. However, lifestyle and environmental factors also play a ...

Study highlights use of techniques such as long-read genome sequencing, optical genome mapping, and RNA sequencing for rare ...

MADISON, Wis. - Exact Sciences Corp. (NASDAQ:EXAS), a leader in cancer screening and diagnostic tests with a market capitalization of $10 billion, announced clinical validation data for its ...

Exact Sciences Corp. , a leading provider of cancer screening and diagnostic tests, shared clinical validation data for its OncodetectTM MRD test at the 2025 American Society of Clinical Oncology ...

Exact Sciences Demonstrates Leadership in Cancer Innovation with New Data on Screening and Molecular Residual Disease at 2025 ASCO GI Symposium ...

Diagnostic tools include standard ontologies for describing dysmorphology and traits, pedigree analysis, disease locus mapping by linkage or homozygosity, karyotyping, genome sequencing and ...

Investment analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Prenetics Global in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn ...